Panel Discussion: Beyond TfR1: Evaluating Next‑Generation BBB Receptors for Systemic Biologic Delivery to the Brain
9:30 am - Thursday 3rd December 2026
- Which alternative BBB receptors (e.g. CD98hc, insulin receptor, LRP1, basigin) show the most promise beyond TfR1 for achieving sufficient brain uptake without compromizing safety or peripheral PK?
- How can we optimize receptor affinity, valency, and trafficking profiles to balance efficient transcytosis with minimal lysosomal degradation or target-mediated clearance?
- What preclinical models and translational biomarkers are most predictive for comparing receptor performance and de-risking clinical success across different shuttle platforms?
- How should developers prioritize receptor selection based on modality (e.g. antibodies, enzymes, oligonucleotides) and indication-specific needs for brain distribution and cellular targeting
